Spyre Therapeutics (SYRE) Receivables - Other (2015 - 2023)

Spyre Therapeutics has reported Receivables - Other for 7 years, with the latest figure at $1.6 million in Q2 2023.

• For the quarter ending Q2 2023, Receivables - Other rose 243.63% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2023 stood at $1.6 million (up 243.63% YoY), and the FY2021 full-year result was $815000.0, changed N/A from the prior year.
• Receivables - Other for Q2 2023 stood at $1.6 million, up from $669000.0 in the prior quarter.
• The five-year high for Receivables - Other was $1.6 million in Q2 2023, with the low at $479000.0 in Q2 2022.
• Historically, Receivables - Other has averaged $902250.0 across 3 years, with a median of $742000.0 in 2021.
• The largest YoY upside for Receivables - Other was 243.63% in 2023 against a maximum downside of 243.63% in 2023.
• Spyre Therapeutics' Receivables - Other stood at $815000.0 in 2021, then retreated by 17.91% to $669000.0 in 2022, then surged by 146.04% to $1.6 million in 2023.
• The last three Receivables - Other figures came in at $1.6 million (Q2 2023), $669000.0 (Q3 2022), and $479000.0 (Q2 2022), per Business Quant data.